Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review.
Administration, Topical
Adrenal Cortex Hormones
/ administration & dosage
Checkpoint Kinase 1
/ antagonists & inhibitors
Drug Eruptions
/ drug therapy
Female
Humans
Leukocyte Count
Male
Melanoma
/ drug therapy
Neutrophils
/ cytology
Prognosis
Protein Kinase Inhibitors
/ adverse effects
Risk Assessment
Skin Neoplasms
/ drug therapy
ipilimumab
neutrophilic dermatosis
nivolumab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
09
07
2019
revised:
13
08
2019
accepted:
21
08
2019
pubmed:
25
8
2019
medline:
11
4
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Checkpoint inhibitors are a new class of drugs that enhance the immune system's intrinsic ability to destroy tumor cells by blocking signaling through the programmed cell death (PD-1) receptor, its ligand (PD-L1), and the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The resulting increase in immunologic activity is responsible for a variety of adverse cutaneous reactions, which sometimes include neutrophilic dermatoses. We queried the PubMed database for existing cases of checkpoint inhibitors causing neutrophilic dermatoses. The literature search identified four cases of Sweet syndrome, four cases of pustular eruptions, two cases of pyoderma gangrenosum, and one case of bullous lupus erythematosus secondary to checkpoint inhibitors. All neutrophilic dermatoses were treated with topical or systemic steroids and most (9 of 11) completely resolved. Dermatologists should be aware of these rare, adverse cutaneous reactions to checkpoint inhibitors and how to approach their treatment, especially as their use increases.
Substances chimiques
Adrenal Cortex Hormones
0
Protein Kinase Inhibitors
0
Checkpoint Kinase 1
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13074Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Adler, N. R., Murray, W. K., Brady, B., McCormack, C., & Pan, Y. (2018). Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma. Clinical and Experimental Dermatology, 43(4), 497-499. https://doi.org/10.1111/ced.13399
Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. American Journal of Clinical Oncology, 39(1), 98-106. https://doi.org/10.1097/COC.0000000000000239
Coleman, E., Ko, C., Dai, F., Tomayko, M. M., Kluger, H., & Leventhal, J. S. (2019). Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal of the American Academy of Dermatology, 80(4), 990-997. https://doi.org/10.1016/j.jaad.2018.10.062
Gormley, R., Wanat, K., Elenitsas, R., Giles, J., McGettigan, S., Schuchter, L., & Takeshita, J. (2014). Ipilimumab-associated sweet syndrome in a melanoma patient. Journal of the American Academy of Dermatology, 71(5), e211-e213. https://doi.org/https://doi.org/10.1016/j.jaad.2014.06.042
Hwang, S. J. E., Carlos, G., Wakade, D., Sharma, R., & Fernandez-Penas, P. (2016). Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. Melanoma Research, 26(4). Retrieved from https://journals.lww.com/melanomaresearch/Fulltext/2016/08000/Ipilimumab_induced_acute_generalized_exanthematous.15.aspx), 417-420.
Kyllo, R. L., Parker, M. K., Rosman, I., & Musiek, A. C. (2014). Ipilimumab-associated sweet syndrome in a patient with high-risk melanoma. Journal of the American Academy of Dermatology, 70(4), e85-e86. https://doi.org/https://doi.org/10.1016/j.jaad.2013.11.022
Page, B., Borradori, L., Beltraminelli, H., Yawalkar, N., & Hunger, R. E. (2018). Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. Journal of the European Academy of Dermatology and Venereology, 32(7), e256-e257. https://doi.org/10.1111/jdv.14282
Pintova, S., Sidhu, H., Friedlander, P. A., & Holcombe, R. F. (2013). Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Research, 23(6), 498-501 Retrieved from https://journals.lww.com/melanomaresearch/Fulltext/2013/12000/Sweet_s_syndrome_in_a_patient_with_metastatic.12.aspx
Raschi, E., Antonazzo, I. C., Poluzzi, E., & De Ponti, F. (2019). Drug-induced systemic lupus erythematosus: Should immune checkpoint inhibitors be added to the evolving list? Annals of the Rheumatic Diseases, 0(0), 2019. https://doi.org/10.1136/annrheumdis-2019-215819
Rudolph, B. M., Staib, F., Von Stebut, E., Hainz, M., Grabbe, S., & Loquai, C. (2014). Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - Simultaneous occurrence of pyoderma gangrenosum and colitis. European Journal of Dermatology, 24(2), 268-269. https://doi.org/10.1684/ejd.2014.2298
Wang, C. Y., Khoo, C., McCormack, C. J., Xu, W., & Pan, Y. (2017). Acute localised exanthematous pustulosis secondary to pembrolizumab. Australasian Journal of Dermatology, 58(4), 322-323. https://doi.org/10.1111/ajd.12594
Welborn, M. E., Kubicki, S. L., & Patel, A. B. (2018). Case report Pyoderma Gangrenosum following initiation of immune checkpoint inhibitor therapy. Journal of Immunotherapy and Precision Oncology, 1(2), 82-84. https://doi.org/10.4103/JIPO.JIPO
Wouters, A., Durieux, V., Kolivras, A., Meert, A.-P., & Sculier, J.-P. (2019). Bullous lupus under Nivolumab treatment for lung cancer: A case report with systematic literature review. Anticancer Research, 39, 3003-3008. https://doi.org/10.21873/anticanres.13432
Zhao, C. Y., Consuegra, G., Chou, S., & Fernández-Peñas, P. (2017). Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils. Melanoma Research, 27(6), 641-644 Retrieved from https://journals.lww.com/melanomaresearch/Fulltext/2017/12000/Intracorneal_pustular_drug_eruption,_a_novel.18.aspx